112 related articles for article (PubMed ID: 15753437)
1. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism.
Linnebank M; Pels H; Kleczar N; Farmand S; Fliessbach K; Urbach H; Orlopp K; Klockgether T; Schmidt-Wolf IG; Schlegel U
Neurology; 2005 Mar; 64(5):912-3. PubMed ID: 15753437
[TBL] [Abstract][Full Text] [Related]
2. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma.
Linnebank M; Moskau S; Jürgens A; Simon M; Semmler A; Orlopp K; Glasmacher A; Bangard C; Vogt-Schaden M; Urbach H; Schmidt-Wolf IG; Pels H; Schlegel U
Neuro Oncol; 2009 Feb; 11(1):2-8. PubMed ID: 18806228
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study.
Fliessbach K; Helmstaedter C; Urbach H; Althaus A; Pels H; Linnebank M; Juergens A; Glasmacher A; Schmidt-Wolf IG; Klockgether T; Schlegel U
Neurology; 2005 Apr; 64(7):1184-8. PubMed ID: 15824344
[TBL] [Abstract][Full Text] [Related]
4. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
5. Association of transcobalamin c. 776C>G with overall survival in patients with primary central nervous system lymphoma.
Linnebank M; Moskau S; Kowoll A; Semmler A; Bangard C; Vogt-Schaden M; Egerer G; Schackert G; Reichmann H; Schmidt-Wolf IG; Pels H; Schlegel U
Br J Cancer; 2012 Nov; 107(11):1840-3. PubMed ID: 23099805
[TBL] [Abstract][Full Text] [Related]
6. Results of treatment of 112 cases of primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
[TBL] [Abstract][Full Text] [Related]
7. Treatment-related disseminated necrotizing leukoencephalopathy with characteristic contrast enhancement of the white matter.
Laxmi SN; Takahashi S; Matsumoto K; Higano S; Kurihara N; Imaizumi M; Abe K; Itoyama Y; Sakamoto K
Radiat Med; 1996; 14(6):303-7. PubMed ID: 9132810
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.
Dervieux T; Greenstein N; Kremer J
Arthritis Rheum; 2006 Oct; 54(10):3095-103. PubMed ID: 17009228
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.
Gavrilovic IT; Hormigo A; Yahalom J; DeAngelis LM; Abrey LE
J Clin Oncol; 2006 Oct; 24(28):4570-4. PubMed ID: 17008697
[TBL] [Abstract][Full Text] [Related]
11. Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate.
Becker A; Vezmar S; Linnebank M; Pels H; Bode U; Schlegel U; Jaehde U
Int J Clin Pharmacol Ther; 2007 Sep; 45(9):504-15. PubMed ID: 17907593
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity.
Vezmar S; Schüsseler P; Becker A; Bode U; Jaehde U
Pediatr Blood Cancer; 2009 Jan; 52(1):26-32. PubMed ID: 19006245
[TBL] [Abstract][Full Text] [Related]
13. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
[TBL] [Abstract][Full Text] [Related]
14. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
15. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
[TBL] [Abstract][Full Text] [Related]
16. Gene variations in GSTM3 are a risk factor for Alzheimer's disease.
Hong GS; Heun R; Jessen F; Popp J; Hentschel F; Kelemen P; Schulz A; Maier W; Kölsch H
Neurobiol Aging; 2009 May; 30(5):691-6. PubMed ID: 17904251
[TBL] [Abstract][Full Text] [Related]
17. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms.
Numata S; Ueno S; Iga J; Yamauchi K; Hongwei S; Ohta K; Kinouchi S; Shibuya-Tayoshi S; Tayoshi S; Aono M; Kameoka N; Sumitani S; Tomotake M; Kaneda Y; Taniguchi T; Ishimoto Y; Ohmori T
Neurosci Lett; 2006 Jun; 401(1-2):1-5. PubMed ID: 16533563
[TBL] [Abstract][Full Text] [Related]
18. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients.
Wang L; Yu L; He G; Zhang J; Zhang AP; Du J; Tang RQ; Zhao XZ; Ma J; Xuan JK; Xiao Y; Gu NF; Feng GY; Xu MQ; Xing QH; He L
Neurosci Lett; 2007 Feb; 414(1):1-4. PubMed ID: 17287080
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia.
Pakakasama S; Kanchanakamhaeng K; Kajanachumpol S; Udomsubpayakul U; Sirachainan N; Thithapandha A; Hongeng S
Ann Hematol; 2007 Aug; 86(8):609-11. PubMed ID: 17323057
[No Abstract] [Full Text] [Related]
20. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
Hayano A; Takashima Y; Yamanaka R
Int J Clin Oncol; 2019 Sep; 24(9):1020-1029. PubMed ID: 30993483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
